Venous Thromboembolism Devices Market Size was valued at USD 956 million in 2021, growing at a CAGR of 8.6% during the forecast period 2022-28. The global market provides a detailed overview and which can be segmented by type of device, disease type, end user, and region. By type of device, the venous thromboembolism devices market has been segmented into compression stockings, gradual or medical compression stockings, anti-embolism stockings, nonmedical support hosiery, intermitted pneumatic compression devices, inferior vena cava filters, retrievable IVC filters, permanent IVC filters. By disease type, the venous thromboembolism devices market has been segmented into deep vein thrombosis and pulmonary embolism. By disease type, the pulmonary embolism segment held the largest revenue share of the venous thromboembolism devices market in past years and is expected to have the fastest growth rate over the forecasted period due to its increasing diseases rate globally. Based on the end user, the segment has been segregated into hospitals, diagnostic centers, and ambulatory surgical centers. The hospital segment is expected to lead the end-user segments owing to the increasing patient population which in turn increases the hospitalization rate worldwide.
In June 2021, Janssen Pharmaceuticals, Inc, a Belgium-based pharmaceutical company, announced receiving Food and Drug Administration (FDA) approval for its new product XARELTO® (rivaroxaban) for the treatment of two indications – deep venous thrombosis and pulmonary embolism. This will assist the company to strengthen its footprint in the market.